Published in Folia Med Neerl on January 01, 1967
In vitro and in vivo correlation of clotting protease activity: effect of heparin. Proc Natl Acad Sci U S A (1977) 0.83
Surgical operation in hemophilia B. Use of factor IX concentrate. Calif Med (1970) 0.76
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem (1990) 2.72
Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer (1999) 2.68
The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem (1981) 2.39
The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem (1980) 2.39
Prothrombal: a new concentrate of human prothrombin complex for clinical use. Br J Haematol (1971) 2.25
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
A standard for low molecular weight heparin? Haemostasis (1989) 2.00
Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med (1978) 1.94
The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry. J Biol Chem (1983) 1.94
The optimal therapeutic range in oral anticoagulation. History and proposal. Thromb Haemost (1979) 1.91
Serum insulin-like growth factor-I and breast cancer. Int J Cancer (2000) 1.82
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol (1997) 1.77
Progress in laboratory control of oral anticoagulants. Lancet (1982) 1.72
The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol (1984) 1.63
Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem (1982) 1.61
Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology (2000) 1.60
Standardisation of oral anticoagulant treatment. Br Med J (Clin Res Ed) (1984) 1.60
Activation of a pro-enzyme by a stoichiometric reaction with another protein. The reaction between prothrombin and staphylocoagulase. Biochim Biophys Acta (1975) 1.53
A collaborative calibration study of reference materials for thromboplastins. Thromb Haemost (1983) 1.53
Contribution of platelet-derived factor Va to thrombin generation on immobilized collagen- and fibrinogen-adherent platelets. Thromb Haemost (2001) 1.51
Dietary habits, sexual maturation, and plasma hormones in pubertal girls: a longitudinal study. Am J Clin Nutr (1991) 1.49
Body fat mass, body fat distribution, and pubertal development: a longitudinal study of physical and hormonal sexual maturation of girls. J Clin Endocrinol Metab (1992) 1.44
The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif--the C-domain. J Thromb Haemost (2003) 1.39
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest (1996) 1.39
[Didrokit (etidronic acid-calcium carbonate) for the treatment of postmenopausal osteoporosis recorded improperly?]. Ned Tijdschr Geneeskd (1994) 1.38
A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand (1967) 1.34
Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem (1985) 1.33
Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol (1998) 1.28
Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem (1992) 1.27
Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.22
Systematic approach to the treatment of chylous leakage after neck dissection. Head Neck (1996) 1.22
[Autopsy in the middle ages]. Ned Tijdschr Geneeskd (1975) 1.22
Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol (1997) 1.20
Laboratory control of oral anticoagulants. Definition of therapeutic range in terms of different thromboplastin preparations. Thromb Diath Haemorrh (1970) 1.20
Activation of human prothrombin by stoichiometric levels of staphylocoagulase. J Biol Chem (1983) 1.20
Body fat distribution and obesity in pre- and postmenopausal breast cancer. Int J Epidemiol (1999) 1.19
Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.17
Quantitation of infarct size in man by means of plasma enzyme levels. Br Heart J (1975) 1.17
Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med (1982) 1.16
Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost (1985) 1.15
Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost (1983) 1.13
Detection of the carrier state in hereditary coagulation disorders. I. Thromb Diath Haemorrh (1968) 1.11
MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res (1986) 1.11
Kinetic aspects of the interaction of blood clotting enzymes. 3. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thromb Diath Haemorrh (1968) 1.11
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: a rebuttal. J Thromb Haemost (2013) 1.10
Heparin-like inhibitor, not vitamin-K deficiency, in the newborn. Lancet (1977) 1.08
Hemostasis and intracranial surgery. J Neurosurg (1983) 1.08
Anticoagulants in cardiac infarction. Lancet (1969) 1.07
The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost (2001) 1.06
Production site of bleeding factor. (Acquired morbus von Willebrand). Thromb Diath Haemorrh (1970) 1.05
Glucocorticoid receptor in cultured human skin fibroblasts. J Steroid Biochem (1979) 1.05
Arterial aneurysm as a cause of consumption coagulopathy. N Engl J Med (1971) 1.05
Body fat mass, body fat distribution, and plasma hormones in early puberty in females. J Clin Endocrinol Metab (1990) 1.04
Arterial thromboembolic complications with aortic ball valve prostheses. Am Heart J (1978) 1.04
The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem (1992) 1.03
Head injury and coagulation disorders. J Neurosurg (1978) 1.03
Circulating anticoagulant in disseminated lupus erythematosus. Proposed mode of action. Haemostasis (1974) 1.03
Genetic counselling for adult polycystic kidney disease. Ultrasound a useful tool in pre-symptomatic diagnosis? Clin Genet (1980) 1.02
Separation of blood coagulation factors II, VII, IX and X by gel filtration in the presence of dextran blue. Biochim Biophys Acta (1970) 1.02
Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost (2004) 1.02
Measurement of thrombin generation in whole blood--the effect of heparin and aspirin. Thromb Haemost (1994) 1.02
Blood cell membranes and haemostasis. Haemostasis (1982) 1.01
During coagulation, thrombin generation shifts from chemical to diffusional control. J Thromb Haemost (2005) 1.01
Partial purification of bovine liver vitamin K-dependent carboxylase by immunospecific adsorption onto antifactor X. FEBS Lett (1981) 1.00
In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood (1989) 1.00
Influence of nitrazepam on oral anticoagulation with phenprocoumon. Clin Pharmacol Ther (1972) 1.00
The Ca2+-mobilizing potency of alpha-thrombin and thrombin-receptor-activating peptide on human platelets -- concentration and time effects of thrombin-induced Ca2+ signaling. Eur J Biochem (1997) 0.99
Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family. Clin Exp Immunol (1982) 0.99
Continuous flow and the prothrombinase-catalyzed activation of prothrombin. Thromb Haemost (1990) 0.98
The quality of life of long-term survivors of Hodgkin's disease. Ann Oncol (1994) 0.97
Hereditary antithrombin III deficiency and thromboembolic disease. Am J Hematol (1976) 0.97
Metabolism of the coagulation factors of the prothrombin complex in hypothyroidism in man. Thromb Haemost (1979) 0.97
Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood (1985) 0.97
Reliability of serum prolactin measurements in women. Cancer Epidemiol Biomarkers Prev (1993) 0.97
Autocatalytic peptide bond cleavages in prothrombin and meizothrombin. Biochemistry (1998) 0.96
Laboratory assessment of antithrombotic therapy: what tests and if so why? Haemostasis (1998) 0.96
Adsorption kinetics of protein mixtures. A tentative explanation of the Vroman effect. Ann N Y Acad Sci (1987) 0.96
Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh (1975) 0.95
Interaction of bovine blood clotting factor Va and its subunits with phospholipid vesicles. Biochemistry (1983) 0.95
Extrahepatic factor VIII synthesis. Lung transplants in hemophilic dogs. Transplantation (1974) 0.95
Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol (1985) 0.95
Detection of the carrier state in hereditary coagulation disorders. II. Thromb Diath Haemorrh (1968) 0.95
A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost (1986) 0.94
The mode of action of heparin in plasma. Thromb Haemost (1988) 0.94
Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol (1970) 0.94
Reaction sequence of blood coagulation. Nature (1967) 0.93
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer (2000) 0.93